Regional differences in presentation of AIDS in Europe

Epidemiology and Infection

Volumn 125, Issue 1, 2000, Pages 143-151

  Blaxhult, A ^a   Kirk, O ^b   Pedersen, C ^c   Dietrich, M ^d   Barton, S E ^e   Gatell, J M ^f   Mulcahy, F ^g   Hirschel, B ^h   Mocroft, A ⁱ   Lundgren, J D ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b HVIDOVRE HOSPITAL   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

^e St Stephen's Health Centre   (United Kingdom)

^f HOSPITAL CLÍNIC   (Spain)

^g ST JAMES S HOSPITAL   (Ireland)

^h GENEVA UNIVERSITY HOSPITALS   (Switzerland)

ⁱ ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AIDS RELATED COMPLEX; ARTICLE; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; EUROPE; FEMALE; GEOGRAPHIC DISTRIBUTION; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INCIDENCE; INFECTION RISK; INTRAVENOUS DRUG ABUSE; KAPOSI SARCOMA; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; PROGNOSIS; RETINITIS; RISK ASSESSMENT; RISK FACTOR; STATISTICAL ANALYSIS; TOXOPLASMOSIS; TUBERCULOSIS; VIRUS TRANSMISSION;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CYTOMEGALOVIRUS RETINITIS; EUROPE; FEMALE; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MALE; PNEUMONIA, PNEUMOCYSTIS; PREVALENCE; REGIONAL HEALTH PLANNING; SARCOMA, KAPOSI; TOXOPLASMOSIS; TUBERCULOSIS;

EID: 0033775529     PISSN: 09502688     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0950268899004185     Document Type: Article

References (35)

1. Long-term symptomless HIV-1 infection in recipients of blood products from a single donor
2. Virological and serological markers of rapid progression to AIDS after HIV-1 seroconversion
3. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection
4. Immune activation is a dominant factor in the pathogenises of African AIDS
5. Penicillium marneffei: Indicator disease for AIDS in South East Asia
6. The African AIDS experience in contrast with the rest of the world
7. Persistant diarrhoea in Zairian AIDS patients: An endoscopic and histological study
8. Disseminated histoplasmosis in the Acquired Immune Deficiency Syndrome: Clinical findings, diagnosis and treatment, and review of the literature
9. The white plague: Down and out, or up and coming?
10. Epidemiological and clinical aspects of mycobacterial infections
11. The international epidemiology of disseminated Mycobacterium avium complex infection in AIDS
12. Acquired Immunodeficiency Syndrome-associated Kaposi's sarcoma
13. A sex comparison of rates of new AIDS-defining disease and death in 2554 AIDS cases
14. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
15. Changing patterns of mortality across Europe in patients infected with HIV-1
16. Survival differences in European patients with AIDS, 1979-89
17. Diversity of the HIV/AIDS epidemic in Europe
18. Tuberculosis among European patients with the acquired immune deficiency syndrome
19. Survival of AIDS patients according to type of AIDS-defining event
20. Factors associated with the development of Pneumocystis carinii pneumonia in 5,025 European patients with AIDS
21. Serologic responses to Pneumocystis carinii antigens in health and disease
22. Geography of AIDS-associated Kaposi's sarcoma in Europe
23. Epidemiology of AIDS-related Kaposi's sarcoma in Europe over 10 years
24. Declining incidence and later occurrence of Kaposi's sarcoma among persons with AIDS in Australia: The Australian AIDS cohort
25. Epidemiologie de la toxoplasmose: Situation au niveau mondial
26. HIV-related non-Hodgkin's lymphoma among European AIDS patients
27. Predicting disease when death is likely
28. Kaposi's sarcoma in HIV infection: Impact on opportunistic infections and survival
29. Duration of the survival benefit of zidovudine therapy in HIV infection
30. Long-term follow-up of symptomatic HIV-infected patients originally randomized to early versus later zidovudine treatment; report of a Veterans Affairs Cooperative Study
31. Size and duration of zidovudine benefit in 1003 HIV-infected patients: US Army, Navy, and Air Force natural history data
32. The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group
33. Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine